Floatz logo

Jab-8263

CRPC

Jacobio Pharmaceuticals Co., Ltd.Phase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the CRPC cohort.

Asset / SponsorPhaseRating
Seviteronel
Innocrin Pharmaceutical
Phase 2BB
Bind-014
BIND Therapeutics
Phase 2B
IMIFOPLATIN
Promontory Therapeutics Inc.
Phase 2CCC
pt-112
Promontory Therapeutics Inc.
Phase 2CCC
Trastuzumab Deruxtecan
Washington D.C. Veterans Affairs Medical Center
Phase 2CCC
otx015
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1C

Same molecule, other indications

Jab-8263 is also rated in:

esophageal squamous cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Solid Tumors, AdultDormant
CC
Indicative ·
46 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →